NeuroOne Medical Technologies Corporation (NMTC)

Nasdaq: NMTC · Surgical & Medical Instruments & Apparatus · Eden Prairie, MN · filing with the SEC since 2010

Full chart Alerts Compare

Grade4.8

◀ Past 2.7● Present 5.4▶ Future 6.1

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of NeuroOne Medical Technologies Corporation

Nine metrics read from its own filings, by tense

Headline grade

4.8/10

◀ Past2.730% of the headline

● Present5.440% of the headline

▶ Future6.130% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

2.7/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

0.4/10

Has it survived what it has been through?

13 warning events since 2017; the latest 2026-05-22.

weight 33% of this tense · 4th percentile among 121 sector filers · read for itself

From the record

NeuroOne Medical Technologies Corporation's filings since 2017 show 13 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2025-11-05); a warning not to rely on past financial statements (8-K item 4.02, 3 times, the latest 2026-05-22); an auditor change (8-K item 4.01, 2 times, the latest 2021-06-24); a late-report notice (Form NT 10-K or NT 10-Q, 4 times, the latest 2018-05-16) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

4.1/10

What has it actually done, year after year?

+83.6% a year over 8 filed years; profitable in 0 of 10.

weight 45% of this tense · 41st percentile among 105 sector filers · read for its customers

From the record

NeuroOne Medical Technologies Corporation's 8 filed years say what it did: revenue went from $1 thousand in fiscal 2010 to $9 million in fiscal 2025, up 83.6% a year; it rose in 5 of 7 years; the deepest fall was 83% from fiscal 2011 to fiscal 2012; net income was positive in 0 of 10 of those years (its annual reports).

What it rests on

revenue growth over the filed span83.6%top 9% of its family
the share of years revenue rosebottom 39% of its family
the share of filed years with a profitbottom 23% of its family
the deepest fall from a revenue peak82.9%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

3.1/10

How has it treated the people who own it?

SI estimate 3.1/10, confidence 35 of 100 (one part).

weight 22% of this tense · 31st percentile among 120 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 31% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 120 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: NeuroOne Medical Technologies Corporation's shareholder treatment is put at 3.1 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 31% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.4/1040% of the headline grade · 3 of 3 filed

Financial health

as filed

5.1/10

Is it financially healthy right now?

ROE -51%: lost 51¢ per shareholder dollar. Leverage 34%: owes 34¢ per asset dollar.

weight 45% of this tense · 51st percentile among 120 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-09-30, NeuroOne Medical Technologies Corporation lost about 51 cents for every dollar of shareholders' money, and gross profitability: its products earned about 48 cents per dollar of everything the company owns. Leverage: it owed about 34 cents per dollar of assets, and net share issuance: its share count grew 50.0% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 36% of its family
return on equitybottom 42% of its family
gross profit against assetstop 32% of its family
the share count against the year beforebottom 29% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

5.3/10

How strong is its position in its industry?

top 47% of 109 in its family; net margin -39.6%.

weight 33% of this tense · 53rd percentile among 109 sector filers · read for its customers

From the record

NeuroOne Medical Technologies Corporation's standing among 109 graded names in its industry family: revenue of $9 million in fiscal 2025 ranks in the bottom 22% by size; a net margin of -39.6% ranks in the bottom 38%; revenue growth of 275.9% a year over the last 3 filed years ranks in the top 1% (its annual reports).

What it rests on

revenue against the family$9.1Mbottom 22% of its family
net margin-39.6%bottom 38% of its family
three-year revenue growth275.9%top 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

6.5/10

What are the people in charge doing?

top 35% of 91 in its family for leadership; chief executive since 2017.

weight 22% of this tense · 65th percentile among 91 sector filers · read for its shareholders

From the record

NeuroOne Medical Technologies Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Rosa, David A (CEO & President, as filed), filing under that title since 2017-07-24, 9.3 years (top 24% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 7.2 years (top 24%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 41%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge6 in three years among 10 peoplebottom 41% of its family
the median years the people in charge have filed7.2 yearstop 24% of its family
the chief executive's years on the record9.3 yearstop 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

6.1/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

6.2/10

How much room does it have to grow?

top 38% of 104 in its family for room to expand.

weight 45% of this tense · 62nd percentile among 104 sector filers · read for itself

From the record

NeuroOne Medical Technologies Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $7 million against no long-term debt tagged leaves 60.9% of its assets as net cash, top 12% of its family; cash from operations less capital spending is -32.1% of revenue (bottom 38%); a gross margin of 56.5% (bottom 42%); research spending of 54.8% of revenue (top 19%) (its annual report).

What it rests on

cash less debt against assets60.9%top 12% of its family
cash from operations less capital spending against revenue-32.1%bottom 38% of its family
gross margin56.5%bottom 42% of its family
research spending against revenue54.8%top 19% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

6.1/10

What could actually drive growth from here?

top 39% of 105 in its family for growth drivers.

weight 33% of this tense · 61st percentile among 105 sector filers · read for its customers

From the record

NeuroOne Medical Technologies Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 275.9% a year over the last three filed years against 83.6% over all 8, speeding up (top 2% of its family); the newest year grew 163.6% (top 4%); research spending grew 0.4% a year (bottom 35%); capital spending grew -33.3% a year (bottom 15%) (its annual reports). NeuroOne Medical Technologies Corporation tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+192.3 points a yeartop 2% of its family
the newest year's revenue growth163.6%top 4% of its family
three-year growth of research spending0.4%bottom 35% of its family
three-year growth of capital spending-33.3%bottom 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

5.9/10

Did its newest year beat what its own record pointed to?

top 41% of 88 in its family for expectations against reality.

weight 22% of this tense · 59th percentile among 88 sector filers · read for its shareholders

From the record

NeuroOne Medical Technologies Corporation's newest year against its own record: revenue of $9 million in fiscal 2025 came in 41.3% below the $15 million its prior three years' pace pointed to (bottom 8% of its family); net income of $4 million against a prior three-year average of $11 million (top 27%); a net margin of -39.6% against losses larger than its revenue before (top 4%) (its annual reports).

What it rests on

revenue against the prior three years' pace-41.3%bottom 8% of its family
net income against the prior three years' average+68%top 27% of its family
net margin against its prior averageup more than 100 pointstop 4% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton NMTC · research, not advice